Crotalus atrox antivenin

Specification

• Cat#: THP-0160
• Product Name: Crotalus atrox antivenin
• Description: A mixture of antibodies used to treat venomous snake bites from Crotalus atrox (Western Diamondback rattlesnake). The product is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus atrox (Western Diamondback rattlesnake). The final purified antivenin product is produced by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques.
• Sequences: Not Available
• Species: Ovine
• Molecular Weight: Not Available
• Cas No: Not Available
• Formula: Not Available
• Endotoxin Level: <0.001 EU per 1 μg of the peptide by the LAL method

Pharmaceutical Information

• Pharmaceutical Application: Crotalus atrox antivenin
• Applications: The product is indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.
• Examples of Clinical Use: Snake venom of rattlesnakes, copperheads and cottonmouths
• Pharmacodynamics: Crotalus atrox venom contains agents that render human fibrinogen and plasma incoagulable by thrombin. The product reverses these effects.This facilitates re-distribution of venom toxins away from target tissues and elimination from the body.It is a mixture of 4 different monospecific antivenoms derived from serum of healthy sheep immunized with one of the following North American snake venoms: C. atrox (Western diamondback rattlesnake), C. adamanteus (Eastern diamondback rattlesnake), C. scutulatus (Mojave rattlesnake), or A. piscivorus (cottonmouth or water moccasin).
• Mechanism of action: CROFAB consists of venom-specific Fab fragments of immunoglobulin G (IgG) that work by binding to and neutralizing venom toxins, facilitating their redistribution away from target tissues and their elimination from the body.
• Affected organisms: Humans
• Targets: Target 1. Group 10 secretory phospholipase A2; Target 2. Cytochrome P450 4A11